Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Cigna Reports Strong Q2 Results, Driven by Evernorth Growth and Managed Medical Costs

Cigna Reports Strong Q2 Results, Driven by Evernorth Growth and Managed Medical Costs

Cigna Group has announced solid second-quarter results for 2025, reaffirming its full-year guidance on the back of robust growth in its Evernorth businesses and limited exposure to higher costs affecting government-backed plans. The company's performance highlights its resilience in a challenging healthcare landscape and its strategic positioning in the pharmaceutical services sector.

NoahAI News8/1/2025
Merck Announces Major Workforce Reduction and Cost-Cutting Initiative

Merck Announces Major Workforce Reduction and Cost-Cutting Initiative

Merck, the New Jersey-based pharmaceutical giant, has unveiled plans for a significant restructuring effort aimed at reducing costs and streamlining operations. The company will lay off approximately 6,000 employees, representing 8% of its global workforce, as part of a sweeping cost-cutting initiative designed to save $3 billion annually by the end of 2027.

NoahAI News8/1/2025
PD-L1xVEGF Bispecific Antibodies Show Promise in Lung Cancer Treatment

PD-L1xVEGF Bispecific Antibodies Show Promise in Lung Cancer Treatment

ImmuneOnco Biopharmaceuticals' PD-L1xVEGF bispecific antibody, IMM2510, has demonstrated encouraging results in a phase 2 trial for advanced non-small cell lung cancer (NSCLC) in China. The study, which combined IMM2510 with chemotherapy, showed tumor reduction in 62% of patients, including eight of 10 with squamous NSCLC and five of 11 with non-squamous NSCLC.

NoahAI News8/1/2025
Biogen's Leqembi Gains Traction as Company Eyes Early-Stage Pipeline Expansion

Biogen's Leqembi Gains Traction as Company Eyes Early-Stage Pipeline Expansion

Biogen's second-quarter earnings report reveals promising growth for its Alzheimer's drug Leqembi, while the company sets its sights on bolstering its early-stage pipeline. The pharmaceutical giant's strategic moves and financial performance underscore its commitment to maintaining a competitive edge in the neuroscience market.

NoahAI News7/31/2025
Moderna Announces Major Workforce Reduction Amid Cost-Cutting Efforts

Moderna Announces Major Workforce Reduction Amid Cost-Cutting Efforts

Moderna, the Massachusetts-based mRNA specialist, has revealed plans to reduce its global workforce by approximately 10% as part of a broader cost-cutting initiative. The announcement comes as the company grapples with declining COVID-19 vaccine sales and faces challenges in its product pipeline.

NoahAI News7/31/2025
Lilly's Mounjaro Shows Promise in Cardiovascular Outcomes Trial, Eyes Expanded Approval

Lilly's Mounjaro Shows Promise in Cardiovascular Outcomes Trial, Eyes Expanded Approval

Eli Lilly's diabetes blockbuster Mounjaro (tirzepatide) has demonstrated encouraging results in a highly anticipated Phase III cardiovascular outcomes trial, paving the way for potential expanded approval. While the drug met its primary endpoint of non-inferiority compared to Lilly's older incretin therapy Trulicity, it fell short of achieving statistical superiority in reducing major adverse cardiovascular events (MACE-3).

NoahAI News7/31/2025
Job Market Trends: 81% of Employed Biopharma Professionals Seek New Positions

Job Market Trends: 81% of Employed Biopharma Professionals Seek New Positions

In a striking revelation, a recent BioSpace LinkedIn poll has uncovered that an overwhelming majority of employed biopharma professionals are actively seeking new job opportunities. This surge in job-seeking behavior comes amid a backdrop of industry-wide layoffs and shifting workplace dynamics.

NoahAI News7/31/2025
AbbVie's Rinvoq Shows Promising Results in Alopecia Areata Trial

AbbVie's Rinvoq Shows Promising Results in Alopecia Areata Trial

AbbVie's JAK inhibitor Rinvoq has demonstrated impressive efficacy in treating alopecia areata, potentially carving out a new niche for the drug in the competitive hair loss treatment market. The results from a pivotal Phase III study position Rinvoq as a strong contender against other therapies in this space, with analysts suggesting it could have a significant advantage over competitors.

NoahAI News7/31/2025
Lilly's Kisunla Shows Promising Long-Term Results in Alzheimer's Treatment

Lilly's Kisunla Shows Promising Long-Term Results in Alzheimer's Treatment

Eli Lilly's Alzheimer's disease therapy Kisunla has demonstrated encouraging long-term efficacy in maintaining amyloid plaque clearance and slowing cognitive decline, according to new data presented at the 2025 Alzheimer's Association International Conference in Toronto.

NoahAI News7/31/2025
North Carolina's Biopharma Job Market Thrives Amid Industry Growth

North Carolina's Biopharma Job Market Thrives Amid Industry Growth

North Carolina's pharmaceutical and biotechnology sectors continue to flourish, offering a wealth of employment opportunities for life sciences professionals. The state's robust biopharma ecosystem, anchored by the renowned Research Triangle Park, is attracting top talent and major industry players. Recent data and job market trends highlight the region's significant role in the life sciences landscape.

NoahAI News7/31/2025
Nuvectis Halts Ovarian Cancer Program After Disappointing Phase 1b Results

Nuvectis Halts Ovarian Cancer Program After Disappointing Phase 1b Results

Nuvectis Pharma has announced the discontinuation of its ovarian cancer program following underwhelming results from a phase 1b study of its drug candidate NXP800. The decision marks a significant setback for the company and highlights the challenges in developing effective treatments for this aggressive form of cancer.

NoahAI News7/31/2025
Evotec Sells French Biosimilars Plant to Sandoz for $300M in Strategic Restructuring Move

Evotec Sells French Biosimilars Plant to Sandoz for $300M in Strategic Restructuring Move

Evotec, a leading drug discovery and development company, has announced the sale of its biologics manufacturing facility in Toulouse, France, to generics giant Sandoz for approximately $300 million. This significant transaction marks a pivotal moment in Evotec's ongoing corporate restructuring efforts and represents a shift towards a more capital-efficient business model.

NoahAI News7/31/2025
«1...345...67»